Drugs that contain Bupropion Hydrobromide

1. List of Aplenzin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7569610 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7585897 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7572935 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7662407 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7645802 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(3 years from now)

US7671094 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(3 years from now)

US7649019 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7241805 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

Market Authorisation Date: 23 April, 2008

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of APLENZIN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic